Gamma delta T cells in the immune system are adept at identifying and eliminating cancer cells. Patients with higher levels of these cells in their tumors generally have better outcomes. Researchers have determined the conditions that enable these T cells to recognize cancer cells.
The University of Edinburgh's research suggests that the positioning of certain immune cells within lung tumours could predict patient survival and treatment response. This could enhance the efficacy of immunotherapies, which currently fail in 80% of lung cancer cases. This research could significantly improve the success of immunotherapies.
Positive early-stage trial results suggest that Epkinly, a dual-acting cancer immunotherapy from AbbVie and Genmab, could soon offer a new treatment option for patients with follicular lymphoma.